How many stocks are there of Insmed?
The current number of stocks of Insmed is 140.43 M undefined.
Insmed Stocks 2024
Insmed Stocks
140.43 M
Ticker
INSM
ISIN
US4576693075
WKN
A1JJA3
In 2024, Insmed had 140.43 M outstanding stocks, a 0% change from the 140.43 M stocks in the previous year.
The Insmed Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 140.43 |
| 2028e | 140.43 |
| 2027e | 140.43 |
| 2026e | 140.43 |
| 2025e | 140.43 |
| 2024e | 140.43 |
| 2023 | 140.43 |
| 2022 | 123 |
| 2021 | 112.1 |
| 2020 | 97.6 |
| 2019 | 84.6 |
| 2018 | 76.9 |
| 2017 | 66.6 |
| 2016 | 61.9 |
| 2015 | 58.6 |
| 2014 | 43.1 |
| 2013 | 35 |
| 2012 | 26.5 |
| 2011 | 23.3 |
| 2010 | 132.5 |
| 2009 | 12.7 |
| 2008 | 12.2 |
| 2007 | 11.5 |
| 2006 | 9.5 |
| 2005 | 4.9 |
| 2004 | 3.9 |
Insmed shares outstanding US4576693075 · A1JJA3
The number of shares was Insmed in 2023 — This indicates how many shares 140.433 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Insmed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Insmed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Insmed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Insmed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 3.9 M Aktien |
| 2005 | 4.9 M Aktien |
| 2006 | 9.5 M Aktien |
| 2007 | 11.5 M Aktien |
| 2008 | 12.2 M Aktien |
| 2009 | 12.7 M Aktien |
| 2010 | 132.5 M Aktien |
| 2011 | 23.3 M Aktien |
| 2012 | 26.5 M Aktien |
| 2013 | 35 M Aktien |
| 2014 | 43.1 M Aktien |
| 2015 | 58.6 M Aktien |
| 2016 | 61.9 M Aktien |
| 2017 | 66.6 M Aktien |
| 2018 | 76.9 M Aktien |
| 2019 | 84.6 M Aktien |
| 2020 | 97.6 M Aktien |
| 2021 | 112.1 M Aktien |
| 2022 | 123 M Aktien |
| 2023 | 140.43 M Aktien |
| 2024e | 140.43 M Aktien |
| 2025e | 140.43 M Aktien |
| 2026e | 140.43 M Aktien |
| 2027e | 140.43 M Aktien |
| 2028e | 140.43 M Aktien |
| 2029e | 140.43 M Aktien |
Insmed Aktienanalyse
What does Insmed do?
Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Insmed's Shares Outstanding
Insmed's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Insmed’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Insmed’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Insmed’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Insmed stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Insmed are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Insmed evolved in recent years?
The number of shares of Insmed has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Insmed as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Insmed?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Insmed pay?
Over the past 12 months, Insmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Insmed is expected to pay a dividend of 0 USD.
What is the dividend yield of Insmed?
The current dividend yield of Insmed is .
When does Insmed pay dividends?
Insmed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Insmed?
Insmed paid dividends every year for the past 0 years.
What is the dividend of Insmed?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Insmed located?
Insmed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Insmed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Insmed from 9/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did Insmed pay the last dividend?
The last dividend was paid out on 9/12/2024.
What was the dividend of Insmed in the year 2023?
In the year 2023, Insmed distributed 0 USD as dividends.
In which currency does Insmed pay out the dividend?
The dividends of Insmed are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Insmed
Our stock analysis for Insmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Insmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
